AI is Driving Market Personalization

When Gary Hawkings first started his career in retail, he didn’t know exactly where the road might take him. Rightfully, he has carved his own path and now sits down with host Christine Russo as the founder and CEO of CART, the Center of Advancing Retail and Technology to discuss CART’s purpose and the driving factors of change in the industry.

While Hawkings and CART specializes in CPG and grocery, its far more than that. Born about 10 years prior, CART was founded to have an influential and helpful hand on the technology driven changes in the market and industry.

“[I] saw that a lot of retailers really needed help in understanding and discovering what new tech, what new innovation is out there and understanding the implications of a lot of this new technology,” spoke Hawkings on creating CART.

He said, “Technology is triggering…this new competitive battleground,” which is driving changes across the industry. With technology changing everything from supply chain operations to in-store functions, Hawkings noticed that, “It’s the digitalization of the retail industry that is powering such transformation, such disruption.”

New AI research can build a profile of each shopper and compile all the information gathered to “strategically drive what specific promotions, not only what products but what pricepoints, or discounts, need to be provided to each individual customer to grow lifetime value, grow engagement,” explained Hawkings.

In traditional discount schemes, the brands take on retail marketing, “but as retailers…have become very cognizant of all their customer data, customer behavior and what’s happening” retailers have learned the power of individual marketing schemes to draw customers in.

As Hawkings stated, “Different markets in Europe are ahead of the U.S. right now,” in terms of computervision, however, what’s to come is certainly on the edge of the horizon.

More Stories Like This:

Introducing “What Just Happened?” with Christine Russo

$40 Million in Funding Allows HugePOD to expand to the US

Follow us on social media for the latest updates in B2B!

Image

Latest

AI in marketing
From Queries to Conversations with AI in Marketing Analytics
April 21, 2025

In this episode of the SparkCast, Aby Varma—founder of Spark Novus, a firm that helps marketing leaders adopt AI responsibly and strategically—sits down with Daniel Kravtsov, CEO and Co-Founder of Improvado. Daniel shares his unique journey from Russia to founding a cutting-edge martech company in the Bay Area. Together, they explore how AI agents…

Read More
ESA
ESA Success Requires Strategy, Infrastructure, and Support Beyond Legislation
April 21, 2025

As education savings accounts (ESAs) gain traction across the United States, the conversation is shifting from policy debates to the complexities of implementation. Fueled by post-pandemic dissatisfaction with traditional school models and a desire for more customizable educational options, ESAs are being adopted in a growing number of states, often under “universal” frameworks. But…

Read More
supply chain data analytics
Supply Chain Data Analytics Fails Without Clean Data, Ventagium Delivers the Fix
April 21, 2025

Supply chain leaders face an overwhelming volume of siloed data across ERPs, TMS platforms, and warehouse systems, yet few know how to align it for smarter decisions. The stakes are rising fast. According to Capgemini’s 2024 report Data: A Powerful Ally in Tackling Scope 3 Emission Reduction Targets, 85% of organizations cite data access…

Read More
cancer immunotherapy
What’s Next in Preclinical Cancer Immunotherapy Research?
April 19, 2025

As the field of cancer immunotherapy rapidly evolves, researchers are turning to next-generation in vitro technologies to replicate the complexities of the tumor microenvironment with unprecedented fidelity. Organoid platforms and ex vivo patient-derived tissue models are transforming how scientists approach preclinical testing, offering deeper mechanistic insights and better predictive power for therapeutic response. With immunotherapies…

Read More